Vicore Pharma (Buy, TP: SEK57.00) - Takeaways from KOL event on C21 in Covid-19
On 28 April, Vicore Pharma hosted a KOL webinar on C21 and its potential role in treating Covid-19 patients. The event was joined by professor Maureen Horton M.D. of Johns Hopkins, who shared her perspective from her year treating Covid-19 patients. In our view, the message was clear: Covid-19 is here to stay, and there remains an urgent need for an effective treatment. Furthermore, Vicore Pharma provided more flavour on the planned pivotal phase III trial, with the first patient in expected in Q3 2021, and top-line data in Q1 2022.Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.